# Boundless Bio

**Canonical:** https://apis.io/providers/boundless-bio/  
**Website:** https://boundlessbio.com/  
**APIs profiled:** 10

Boundless Bio (Nasdaq: BOLD) is a San Diego, California based clinical-stage, next-generation precision oncology company founded in 2018 to target extrachromosomal DNA (ecDNA) — circular, centromere-free DNA that carries high copy-number oncogene amplifications and is observed in roughly 17% of cancer patients, driving tumor heterogeneity and resistance to targeted therapy. Its proprietary Spyglass discovery platform, built on a suite of ecDNA+/- tumor models plus molecular analytics and imaging, identifies targets essential to ecDNA function, which the company drugs with small-molecule ecDNA-directed therapies (ecDTx). The clinical pipeline is led by BBI-940, a kinesin inhibitor targeting ecDNA segregation, in the Phase 1 KOMODO-1 trial in ER+/HER2- and TNBC-LAR breast cancer opened in February 2026, with earlier CHK1 (replication stress) and RNR (DNA assembly and repair) programs behind it; ECHO, its ecDNA diagnostic algorithm, reads ecDNA off routine clinical next-generation sequencing and is described by the company as the first ecDNA diagnostic used in clinical trials. Boundless Bio raised a $100M Series C co-led by Leaps by Bayer and RA Capital and listed on Nasdaq in 2024. It publishes no developer program, no product API, no SDKs and no API documentation of any kind; the only machine-readable surface on boundlessbio.com is the WordPress REST API (wp/v2), anonymously readable, which serves the corporate pages, the Leadership directory and the media library as JSON.

## Kin Score — 22.3 / 100 (emerging)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 22.3).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 14.4 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 16.8 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 28.6 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | derived |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (10)

- **Boundless Bio Comments API** — The Comments API from Boundless Bio — 2 operation(s) for comments.
- **Boundless Bio Discovery API** — The Discovery API from Boundless Bio — 4 operation(s) for discovery.
- **Boundless Bio Leadership API** — The Leadership API from Boundless Bio — 2 operation(s) for leadership.
- **Boundless Bio Media API** — The Media API from Boundless Bio — 3 operation(s) for media.
- **Boundless Bio Pages API** — The Pages API from Boundless Bio — 2 operation(s) for pages.
- **Boundless Bio Posts API** — The Posts API from Boundless Bio — 2 operation(s) for posts.
- **Boundless Bio Search API** — The Search API from Boundless Bio — 1 operation(s) for search.
- **Boundless Bio Settings API** — The Settings API from Boundless Bio — 1 operation(s) for settings.
- **Boundless Bio Taxonomy API** — The Taxonomy API from Boundless Bio — 6 operation(s) for taxonomy.
- **Boundless Bio Users API** — The Users API from Boundless Bio — 3 operation(s) for users.

## Agentic access (1)

- **Boundless Bio Agentic Access** — 73 operations · 48 acting

## Security (2)

- **Boundless Bio Authentication** — http · 1 scheme
- **Boundless Bio Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotechnology, Oncology, Precision Medicine, Drug Discovery, Life Sciences, Pharmaceuticals, Clinical Trials, Genomics, Diagnostics, Research, Content

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/boundless-bio/). Scores are computed from the provider's own public artifacts under a published rubric.